Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Cipla Quality Chemical Industries Limited Initial Public Offering and USE Listing
Davis Polk advised the bookrunner in connection with the initial public offering of Cipla Quality Chemical Industries…
Davis Polk Advises Shire on Its $2.325 Billion Concurrent Tender Offers
Davis Polk advised Shire plc on concurrent tender offers by Baxalta Incorporated and Shire Acquisitions Investments Ireland…
AbbVie Inc. $6 Billion Senior Notes Offering
Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of …
Galapagos NV €296.2 Million Follow-On Offering of American Depositary Shares
Davis Polk advised the representatives of the several underwriters in connection with Galapagos NV’s offering of 2,961,373…
Davis Polk Advises Roche Holdings on Its $1.4 Billion Notes Offering
Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A/Regulation S offering of $750 million aggregate…
Halfmoon Parent, Inc. $20 Billion Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $20 billion…
Zai Lab Limited $150 Million Follow-On Offering of American Depositary Shares
Davis Polk advised Zai Lab Limited in connection with its first follow-on offering of $150 million of American Depositary…
Illumina, Inc. $750 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Illumina,…
Zoetis Inc. $1.5 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $300…
Davis Polk Advises ViewRay, Inc. on Its $172.5 Million Follow-On Common Stock Offering
Davis Polk advised ViewRay, Inc. in connection with its $172.5 million SEC-registered follow-on offering of 18,648,649…